Ohne Titel - chirurgiewien.at · Is orthotopic liver transplantation a feasable ... Prenephrectomy tissue typing using ... DNA ploidy and other results of DNA Flow cytometry as prognostic

Univ. Prof. Dr. Michael Gnant Originalarbeiten - 1 -

OKT 3 immunoprophylaxis in human liver transplantation

Muehlbacher F, Steininger R, Laengle F, Sautner T, Gnant M, Goetzinger P, Piza F, Popow T

Transplant P 1989; 21: 2253-4

1

1,096IF:

Adjuvante Therapie einer Pseudomonaspneumonie und -sepsis bei einer immunsupprimiertenPatientin nach orthotoper Lebertransplantation mit einer IgM-angereicherten Immunglobulinloesungund Fibronectin-angereichertem Serum

Sautner T, Graninger G, Gnant M, Jantsch H

Acta Chir Austriaca 1989; 6: 304-5

2

0,000IF:

Prophylaxis with OKT 3 for liver transplantation

Muehlbacher F, Steininger R, Laengle F, Hamilton G, Sautner T, Gnant M, Goetzinger P, Piza F, Popow T

Transplant P 1989; 21 Suppl 2: 25-30

3

1,096IF:

Professionelle Organgewinnung als Vorraussetzung zum Erreichen der notwendigenTransplantationsfrequenz: Erfahrungen mit der Organspende am Transplantationszentrum Wien

Gnant M, Sautner T, Muehlbacher F, Steininger R, Laengle F, Piza F

Wiener Klin Wochenschr 1989; 23: 824-8

4

0,245IF:

Erfahrungen und klinische Ergebnisse nach 99 Verwandtennierentransplantationen

Laengle F, Gnant M, Sautner T, Muehlbacher F, Kretschmer G, Traindl O, Kovarik J, Derfler K, Balcke B, Steger H, HajekA, Piza F

Wiener Klin Wochenschr 1989; 5: 148-51

5

0,216IF:

Pancreatic venous drainage to the portal vein: A new method in human pancreatic transplantation

Muehlbacher F, Gnant M, Auinger M, Steininger R, Klauser R, Prager R, Karnel F

Transplant P 1990; 22: 636-7

6

0,987IF:

Immediate graft function after OLT clears endotoxins

Steininger R, Fuegger R, Hackl W, Hamilton G, Herbst F, Laengle F, Gnant M, Rogy M, Sautner T, Schulz F, MuehlbacherF

Transplant P 1990; 22: 1544-6

7

0,987IF:

Zur Neubewertung der Indikation zur Lebertransplantation

Funovics J, Gnant M, Piza F

Leber-Magen-Darm 1990; 1: 7-11

8

0,227IF:

Homologe Saphenavenen als AV-Shunt zur Hämodialyse: Ein Vergleich zu konventionellenMethoden

Laengle F, Gnant M, Sautner T, Muehlbacher F, Watzinger U, Derfler K, Manker M, Piza F

Angio Arch 1990; 19: 171-3

9

0,000IF:

2


Aspects and prospects of organ procurement: The Vienna experience

Gnant M

ETCO Newsl 1990; 1: 7-10

10

0,000IF:

The impact of serum lipid parameters on the diagnosis of acute and chronic rejection after orthotopicliver transplantation

Gnant M, Schoental E, Banhegyi C, Steininger R, Sautner T, Goetzinger P, Wamser P, Zekert F, Muehlbacher F

Transplant Proc 1991; 23: 1434-5

11

1,064IF:

Is orthotopic liver transplantation a feasable treatment for secondary cancer of the liver?

Muehlbacher F, Huk I, Steininger R, Gnant M, Goetzinger P, Wamser P, Banhegyi C, Piza F

Transplant P 1991; 23: 1567-8

12

1,064IF:

Soluble interleukin-2 receptor in liver transplant recipients

Stockenhuber F, Gnant M, Apperl A, Steininger R, Sautner T, Balcke P, Muehlbacher F

Transplant P 1991; 23:1417-8

13

1,064IF:

Derzeitiger Therapieplan beim differenzierten Schilddrüsenkarzinom

Roka R, Niederle B, Gnant M, Laengle F, Hausmaninger C, Neuhold N

Chirurg 1991; 62: 518-23

14

0,392IF:

Impact of donor age on graft function in 1180 consecutive kidney recipients

Sautner T, Goetzinger P, Wamser P, Gnant M, Steininger R, Muehlbacher F

Transplant P 1991; 23: 2598-601

15

1,064IF:

The impact of presumed consent law and decentralized organ procurement system on organdonation: quadruplication of number of organ donors

Gnant M, Wamser P, Goetzinger P, Sautner T, Steininger R, Muehlbacher F

Transplant P 1991; 23: 2685-6

16

1,064IF:

Prenephrectomy tissue typing using donor lymph node cells: A reliable and safe way of shorteningcadaver kidney ischemia time

Gnant M, Rosenmayr A, Wamser P, Goetzinger P, Sautner T, Steininger R, Banhegyi C, Muehlbacher F

Transplant P 1991; 23: 2683-4

17

1,064IF:

Der prognostische Stellenwert der Flowzytometrie beim Mammakarzinom: 10-Jahres-Ergebnisseeiner randomisierten Studie

Gnant M, Blijham G, Schemper M, Reiner A, Reiner G, Spona J, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R

Acta chir Austriaca 1991; 2: 43-8

18

0,000IF:

2


Erfahrungen mit der Lebertransplantation beim Hepatitis-B-Antigen positiver Leberzirrhose

Steininger R, Muehlbacher F, Längle F, Gnant M, Sautner T, Goetzinger P, Walgram M, Penner E, Radaszkiewicz T

Wien Klin Wochschr 1991; 19: 573-6

19

0,243IF:

Transplantation of shipped full-house kidneys versus local poorly matched grafts - does a shortercold ischemic time outweigh a worse match?

Banhegyi C, Sautner T, Gnant M, Goetzinger P, Wamser P, Muehlbacher F

Transplant P 1991; 23: 2610-1

20

1,064IF:

Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation

Steininger R, Muehlbacher F, Hamilton G, Laengle F, Gnant M, Popow T, Sautner T, Goetzinger P, Wamser P,Stockenhuber F, Mirza D, Piza F

Transplant P 1991; 23: 2269-71

21

1,064IF:

Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patienten mit operablemMammakarzinom

Jakesz R, Hausmaninger H, Depisch D, Kubista E, Samonigg H, Steindorfer P, Schemper M, Gnant M, Kolb R, Krauß K,Manfreda D, Stierer M, Michlmayr G, Fridrik M, Dadak C, Hofbauer F, Horvath W, Zielinski C, Wette V, Oppitz P, DuenserM, Lenzhofer R, Mueller L, Ludwig H; Adler A, Aiginger P, Bauer D, Bauerndorfer T, Beinhauer A, Boeckl O, Brunhofer A,


22

0,000IF:

Intraoperative course and prognostic significance of Endotoxin, Tumor necrosis factor-alpha andInterleukin-6 in liver transplant recipients

Hamilton G, Prettenhofer M, Zommer A, Hofbauer S, Goetzinger P, Gnant M, Függer R

Immunobiology 1991; 182: 425-39

23

1,576IF:

Cadaveric kidney donation beyond the age of 60 - a comparative analysis of 1180 grafts fromdifferent donor age groups

Sautner T, Gnant M, Goetzinger P, Wamser P, Steininger R, Muehlbacher F

Tranplant Int 1992; 5 Suppl 1: S47-S50

24

0,907IF:

Risk factors for development of panel reactive antibodies and their impact on transplantation outcomein 909 kidney grafts

Sautner T, Gnant M, Banhegyi C, Wamser P, Goetzinger P, Steininger R, Muehlbacher F

Transplant Int 1992; 5 Suppl 1; S116-S120

25

0,907IF:

DNA ploidy and other results of DNA Flow cytometry as prognostic factors in operable breast cancer:10 year results of a randomized study

Gnant M, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R

Eur J Cancer 1992; 28: 711-6

26

2,191IF:

A reliable way of shortening cadaver kidney ischemia time: Prenephrectomy tissue typing usingdonor lymph node cells

Gnant M, Sautner T, Wamser P, Goetzinger P, Rosenmayr A, Muehlbacher F

Tranplant Int 1992; 5 Suppl 1: S722-S724

27

0,907IF:

2


Repeated HLA mis-match in multiple kidney transplantation - Preliminary results of 146retransplantations in the cyclosporine era

Gnant M, Sautner T, Rosenmayr A, Muehlbacher F

Transplant P 1992; 24: 2466-2468

28

1,125IF:

Breast cancer and timing of surgery during menstrual cycle: A 5-year analysis of 385 premenopausalwomen

Gnant M, Seifert M, Jakesz R, Adler A, Mittlboeck M, Sevelda P

Int J Cancer 1992; 52: 707-712

29

2,917IF:

Laparoskopische Cholecystektomie - Auswertung einer prospektiven Beobachtungsstudie

Fuegger R, Klimann S, Gnant M, Herbst F, Schulz F, Fritsch A

Wien Klin Wochenschr 1992; 104/20: 640-3

30

0,196IF:

Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma

Neuhold N, Laengle F, Gnant M, Hollenstein U, Niederle B

J Cancer Res Clin 1992; 118: 629-634

31

1,820IF:

Gallengangsverletzungen bei laparoskopischer Cholecystektomie

Fuegger R, Klimann S, Gnant M, Schulz F, Fritsch A

Helv Chir Acta 1992; 59: 571-571

32

0,046IF:

Risikofaktoren für die Entstehung lymphozytotoxischer Antikörper und deren Einfluß auf dieOrganfunktion nach Nierentransplantation

Sautner T, Gnant M, Banhegyi C, Wamser P, Goetzinger P, Steininger R, Hajek-Rosenmayr A, Muehlbacher F


33

0,000IF:

Die experimentelle laparoskopische Sigmaresektion

Fuegger R, Herbst F, Gnant M, Goetzinger P, Sautner T, Windberger U, Siegl H, Losert U, Fritsch A

Min Inv Chir 1992; 1: 167-8

34

0,576IF:

Tolerance induction in human kidney retransplantation: Impact of repeated HLA mismatches in 156second renal grafts

Gnant M, Sautner T, Rosenmayr A, Muehlbacher F

Transplant P 1993; 25: 319-321

35

1,125IF:

Circulating ICAM-1: Novel parameter of renal graft rejection

Stockenhuber F, Kramer G, Pec M, Scentkiraly A, Gnant M, Steininger R, Balcke P, Muehlbacher F

Transplant P 1993; 25: 919-920

36

1,125IF:

2


Impact of vesicoureteral reflux on graft survival in renal transplantation

Gruenberger T, Gnant M, Sautner T, Hoebarth K, Steininger R, Hofbauer J, Muehlbacher F

Transplant P 1993; 25: 1058-1059

37

1,125IF:

GM-CSF in the treatment of a patient with severe methotrexate intoxication

Steger G, Mader R, Gnant M, Marosi C, Lenz K, Jakesz R

J Intern Med 1993; 233: 499-502

38

1,453IF:

Aneuploidy Fraction but not DNA Index is important for the prognosis of patients with stage I and IIbreast cancer - 10 year results

Gnant M, Blijham G, Schemper M, Reiner A, Reiner G, Spona J, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R

Ann Oncol 1993; 4: 643-650

39

2,064IF:

Mechanisms of tumor necrosis factor-a and interleukin-6 induction during human liver transplantation

Hamilton G, Vogel S, Fuegger R, Gnant M

Mediat Inflamm 1993; 2: 303-307

40

0,870IF:

What do intensive care unit personell think about organ donation? Opinion poll amongst transplantcenters

Wamser P, Goetzinger P, Gnant M, Sautner T, Steininger R, Muehlbacher F

Transplant P 1993; 25:3122-3

41

1,125IF:

Laparoskopische Kolonchirurgie - vom Experiment zu ersten klinischen Erfahrungen

Fuegger R, Herbst F, Gnant M, Sautner T, Goetzinger P, Windberger U, Siegl H, Losert U, Fritsch A

Wien Klin Wochenschr 1993; 105: 544-548

42

0,268IF:

Discontinuing of a permanent information and education program among donors ICUs leads to a 50%decrease of organ donor rates

Wamser P, Goetzinger P, Steininger R, Gnant M, Sautner T, Muehlbacher F

Transplant P 1993; 25: 2988-9

43

1,125IF:

Impact of donor cause of death on renal graft function - a multivariate analysis of 1545 kidneytransplants

Gnant M, Wamser P, Barlan M, Muehlbacher F

Transplant P 1993; 25: 3102-3

44

1,125IF:

The potential impact of Tamoxifen in Breast Cancer Prevention

Goetzinger P, Gnant M, Hochstoeger E, Jakesz R

Onkologie 1993; 16: 297-303

45

0,545IF:

2


Double modulation of 5-flourouracil by high-dose leucovorin and interferon a2b in advancedcolorectal cancer: A phase I and a phase II study of weekly administration

Steger GG, Mader RM, Djavanmard MP, Gnant M, Locker G, Marosi C, Rainer H, Jakesz R

J Cancer Res Clin Oncol 1994; 120: 314-318

46

1,820IF:

Pharmacokinetics of rac-leucovorin versus [S]-leucovorin in patients with advanced gastrointestinalcancer

Mader RM, Steger GG, Rizovski B, Sieder AE, Locker G, Gnant M, Jakesz R, Rainer H

Brit J Clin Pharmac 1994; 37: 243-248

47

1,922IF:

Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst allICUs of a tranplant centre

Wamser P, Goetzinger P, Barlan M, Gnant M, Hoelzenbein T, Watschinger B, Muehlbacher F

Transplant Int 1994; 7 [Suppl 1]: S668-671

48

0,907IF:

Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst allICUs of a tranplant centre

Wamser P, Goetzinger P, Barlan M, Gnant M, Hoelzenbein T, Watschinger B, Muehlbacher F

Eurotransplant Newsletter 1994; 116: 6-9

48A

0,000IF:

Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation withprognosis

Rudas M, Gnant M, Mittlboeck M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A

Breast Cancer Res Tr 1994; 32: 165-175

49

2,479IF:

Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity inbreast cancer

Fiegl M, Tueni C, Schenk T, Jakesz R, Gnant M, Reiner A, Rudas M, Pirc-Danoewinata H, Marosi C, Huber H, Drach J

Brit J Cancer 1995; 72: 51-55

50

3,449IF:

Cutaneous Side Effects in breast cancer patients treated with cytostatic polychemotherapy and rhGM-CSF: Immune henomena or drug toxicity ? (cutaneous reations to GM-CSF in breast cancer)

Locker G, Simonitsch I, Mader RM, Warlamides E, Gnant M, Jakesz R, Rainer H, Steger G


51

2,879IF:

Die Bedeutung der Lymphadenektomie bei Patienten mit colorectalem Carcinom

Jakesz R, Gnant M

Acta Chir Aust 1995; 9: 99

52

0,000IF:

Abdominalchirurgie in der geriatrischen Onkologie

Gnant M

Onko-logisch 1995; 3: 12-3

53

0,000IF:

2


Platelet disorders in uraemia before and after haemodialysis under the influence of low dose apirin

Tschugguel W, Blaicher A, Klamer L, Felfernig M, Jungling G, Kurz M, Gnant M, Zimpfer M

Thromb Res 1995; 80: 225-33

54

1,443IF:

Kann man einer hochselektionierten Patientinnengruppe nach Brusterhaltender Therapie wegenMammakarzinoms die postoperative Nachbestrahlung ersparen?

Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Goetzinger P, Gnant M, Reiner A, Teleky B, Seitz W,Jakesz R

Acta Chir Aust 1995; 27: 269-73

55

0,000IF:

The importance of the effect of underlying disease on rejection outcomes following orthotopic livertransplantation

Berlakovich G, Imhof M, Karner-Hanusch J, Goetzinger P, Gollackner B, Gnant M, Hanelt S, Laufer G, Muehlbacher F,Steininger R

Transplantation 1996; 61: 554-60

56

3,544IF:

Neoadjuvant chemotherapy enables breast conserving surgery in patients with very large breastcancers

Taucher S, Gnant M, Djavanmard M, Kandioler D, Goetzinger P, Rudas M, Steger G, Jakesz R

Onkologie 1996; 19: 242-6

57

0,451IF:

Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors

Kandioler D, Dekan G, End A, Pasching E, Buchmayer H, Gnant M, Langmann F, Mannhalter C, Eckersberger F, Wolner E

J Thorac Cardiov Surg 1996; 111: 827-31

58

2,874IF:

Ovarian ablation in early breast cancer: overview of the randomised trials

Early Breast Cancer Trialists' Collaborative Group

Lancet 1996; 348: 1189-1196

59

17,948IF:

Tumor recurrence after oLTX

Gruenberger T, Windhager T, Gnant M, Mittlboeck M, Steininger R, Herbst F, Muehlbacher F

Transplant Int 1996; 9S1: S151-4

60

1,522IF:

Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibiScintimammography

Helbich T, Becherer A, Trattnig S, Leitha T, Kelkar P, Seifert, Gnant M, Staudenherz A, Rudas M, Wolf G, Mostbeck GH

Radiology 1997; 202: 421-9

61

4,698IF:

p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situcarcinomas of the breast

Rudas M, Neumayer R, Gnant M, Mittlboeck, Jakesz R, Reiner A

Eur J Cancer 1997; 33: 39-44

62

2,743IF:

2


Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablemMammakarzinom (II)

Jakesz R, Gnant M, Schmid M, Smonigg H, Steindorfer P, Hausmaninger H, Sevelda P, Depisch D, Tausch C, Reiner G,Renner K, Stierer M, Pilz E, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Dadak C, Haid A, Kusbista E, Scholz R,Sagaster P, Winter R, Lenzhofer R

Acta Chirurgica Austriaca 1997; 29: 62-67

63

0,000IF:

The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cellcarcinoma

Steger G, Gnant M, Djavanmard M, Mader R, Jakesz R, Pierce W, deKernion J, Figlin R, Belldegrun A


64

1,459IF:

5-fluorouracil kinetics in the interstital tumor space: clinical response in breast cancer patients

Müller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blöchl-Daum B

Cancer Res 1997; 57: 2598-601

65

8,426IF:

Protein-p53-Expression, Cell proliferation and steroid hormone receptors in Ductal Carcinoma in situof the breast

Reiner A, Rudas M, Neumayer R, Gnant M, Mittlboeck M, Jakesz R

Acta Chir Aust 1997; 29: 123-125

66

0,000IF:

It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancerpatients?

Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Gnant M, Reiner A, Teleky B, Seitz W, Jakesz R


67

2,430IF:

Evaluation of needle size for breast biopsy: Comparison of 14-, 16, and 18-gauge biopsy needles

Helbich T, Rudas M, Haitel A, Kohlberger P, Thurnher M, Gnant M, Wunderbaldinger P, Wolf G, Mostbeck G

Am J Roentgenol 1998; 171: 59-63

68

2,332IF:

Very low dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients

Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M,Stierer M, Kolb R, Steger G, and the Austrian Breast Cancer Study Group

Eur J Cancer 1998; 34:66-70

69

2,743IF:

Tamoxifen for early breast cancer: an overview of the randomised trials


The Lancet 1998; 351: 1451-1467

70

16,135IF:

Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellularcarcinoma after liver transplantation then albumin mRNA in peripheral blood

Peck-Radosavljevic M, Pidlich J, Bergmann M, Ferenci P, Seelos C, Wichlas M, Lipinski E, Gnant M, Gangl A, MuehlbacherF and the Liver Transplant Oncology Group

J Hepatol 1998; 28: 497-503

71

3,189IF:

2


Outcomes of surgical, Percutaneous endoscopic, and percutaneous radiologic gastrostomies

Cosentini E, Sautner T, Gnant M, Winkelbauer F, Teleky B, Jakesz R

Arch Surg 1998; 133: 1076-1083

72

2,526IF:

In vivo tumors that overexpress Endothelial Monocyte-Activatin Polypeptide II demonstrateupregulation of tumor necrosis factor receptor p55 on tumor neovasculature

Wu P, Berger A, Huang J, Gnant M, Turner E, Alexander HR, Libutti S

Surg Forum 1998; 49: 436-438

73

0,000IF:

Polychemotherapy for early breast cancer: an overview of the randomised trials


The Lancet 1998; 351: 1451-1467

74

11,793IF:

Neoadjuvante Chemotherapie bei Patientinnen mit Mammakarzinom

Jakesz R, Taucher S, Gnant M, Gebhard B, Kandioler D, Rudas M, Djavanmard M, Steger G

Zentralbl Chir 1998; 123 (S5) 147-150

75

0,425IF:

Die Wertigkeit der Stanzbiopsie in der Diagnostik palpabler Brusttumoren. Eine prospektive Analysean 150 Patienten.

Götzinger P, Gebhard B, Gnant M, Rudas M, Reiner A, Jakesz R

Chirurg 1998; 69: 1068-71

76

0,932IF:

Haemophilus parainfluenza liver abscess after successful liver transplantation

Friedl J, Stift A, Berlakovich G, Taucher S, Gnant M, Steininger R, Mühlbacher F

J Clin Microbiol 1998: 818-9

77

3,579IF:

Management of organ donation following trauma in conventional heart-beating donor and non-heart-beating donor situations

Pokorny H, Puhalla H, Krenn CG, Soliman T, Langer F, Gruenberger T, Gollackner B, Schindl M, Wamser P, Goetzinger P,Sautner T, Gnant M, Steininger R, Muehlbacher F

Trauma Care 1999; 9: 30-32

78

0,000IF:

Induction of Immunomediated Diseases by Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor During Cancer Treatment?

Locker GJ, Steger GG, Gnant M, Steiner B, Simonitsch I, Krainer M, Budinsky A, Brodowitz T, Jakesz R, Zielinski CC

J Immunotherapy 1999; 22: 85-9

79

3,059IF:

Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Geneand Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression andProlongation of Survival in Mice

Gnant M, Puhlmann M, Alexander HR, Bartlett DL

Cancer Res 1999; 59: 3396-3403

80

8,614IF:

2


Indikationen und Kontraindikationen für brusterhaltende chirurgische Therapie

Jakesz R, Gebhard B, Gnant M, Taucher S

Chirurg 1999; 70: 394-399

81

0,932IF:

Regional versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy forMurine Liver Metastases

Gnant M, Puhlmann M, Bartlett DL, Alexander HR

Ann Surg 1999; 230: 352-361

82

5,987IF:

Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel andepidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)

Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, Steger GG


83

0,588IF:

Thymidine kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vectorfor Tumor-Directed Gene Therapy

Puhlmann M, Gnant M, Brown C, Alexander H, Bartlett D

Hum Gene Ther 1999; 10: 649-657

84

6,796IF:

Prognostic significance of mutations in the p53 gene, particularly in the Zinc-binding domains, inlymph node- and steroid receptor positive breast cancer patients

Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlboeck M, Fridrik M, Seifert M, Kubista E,Reiner A, Zeillinger R, Jakesz R, and the ABCSG

Eur J Cancer 1999; 35: 398-405

85

2,725IF:

Tumor-specific gene delivery using recombinant vaccinia virus in a lapine model of liver metastases

Gnant M, Noll L, Irvine K, Puhlmann M, Terrill R, Alexander R, Bartlett D

J Nat Cancer Inst 1999; 91:1744-50

86

14,159IF:

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive andlymph node-positive breast cancer

Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R,Stierer M, Fridrik M, Mlineritsch B, Mittlboeck M, Steger G, and the Austrian Breast Cancer Study Group

J Clin Oncol 1999; 17: 1701-1709

87

8,773IF:

Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability oftumor neovasculature

Gnant M, Noll LA, Terrill RE, Wu PC, Berger AC, Nguyen HQ, Lans TE, Flynn BM, Libutti SK, Bartlett DL, Alexander HR

Surgery 1999; 126: 890-899

88

2,456IF:

In vivo sensitivity of human melanoma to tumor necrosis factor (TNF) alpha is determined by tumorproduction of the novel cytokine Endothelial-Monocyte Activating Polypeptide II (EMAPII)

Wu P, Alexander H, Huang J, Hwu P, Gnant M, Berger A, Turner E, Wilson O, Libutti S

Cancer Res 1999; 59: 205-12

89

8,614IF:

2


Sensitiziation of tumor necrosis factor alpha (TNF) resistant human melanoma by tumor specific invivo transfer of the gene endcoding for Endothelial Monocyte Activating Peptide II (EMAP-II) usingrecombinant Vaccinia virus

Gnant M, Berger A, Huang J, Puhlmann M, Wu P, Merino M, Bartlett D, Alexander R, Libutti S

Cancer Res 1999; 59:4668-74

90

8,614IF:

Highlights vom ASCO 99 - Mammakarzinom adjuvant

Gnant M

Onkologisch 1999; 7: 9-11

91

0,000IF:

Class I major histocompatibiliy complex expression in human breast cancer correlates with nuclearlocalization of the 90 kDa heat shock protein

Gebhard B, Schuetz G, Ecker R, Steiner GE, Rudas M, Gnant M, Oehler R

Anticancer Res 1999; 19: 5293-5297

92

1,375IF:

Effects of hyperthermia and tumor necrosis factor on inflammatory cytokine secretion andprocoagulant activity in endocelial cells

Gnant M, Turner E, Alexander HR

Cytokine 2000; 12; 339-347

93

2,490IF:

TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment inBreast Cancer Patients

Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlboeck M,Gnant M, Steger G, Jakesz R

Clin Cancer Res 2000; 6: 50-56

94

5,076IF:

Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deletedmutant

Puhlmann M, Brown C, Gnant M, Huang J, Libutti S, Alexander H, Bartlett D

Cancer Gene Ther 2000; 7: 66-73

95

4,151IF:

Die chirurgische Axilladissektion: Technischer Standard oder obsolete Methode?

Bachleitner-Hofmann T, Gnant M

Zbl Chir 2000; 125: 822-829

96

0,302IF:

The angiogenesis inhibitor Endostatin does not affect murine cutaneous wound healing

Berger AC, Feldman AL, Gnant M, Kruger EA, Sim BKL, Hewitt S, Figg WD, Alexander HR, Libutti SK

J Surg Res 2000; 91: 26-31

97

1,674IF:

Favourable and unfavourable effects on long-term survival of radiotherapy for eraly breast cancer: anoverview of the randomised trials


Lancet 2000; 355:1757-1770

98

13,251IF:

2


Die axilläre Lymphknotendissektion in der Therapie des Mammakarzinoms



99

0,000IF:

Adoptive zelluläre Immuntherapie

Stift A, Friedl J, Brostjan C, Dubsky P, Schueller G, Bachleitner-Hofmann T, Radelbauer K, Jakesz R, Gnant M

Acta Chirurgica Austriaca 2000; 32:255-259

100

0,000IF:

Tumor necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumorderived cytokine endothelial monocyte activating peptide II (EMAP-II)

Berger AC, Alexander HR, Wu PC, Tang G, Gnant M, Mixon A, Turner E, Libutti SK

Cytokine 2000; 12:992-1000

101

2,490IF:

Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes inhuman hepatocellular cancer

Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R, Gnant M

Cancer Biother Radio 2000; 15: 477-86

102

1,574IF:

Gentherapie - Tor zur Zukunft?



103

0,000IF:

Role of Tumor Necrosis Factor (TNF) on Toxicity and Cytokine Production after Isolated HepaticPerfusion

Lans TE, Bartlett DL, Libutti SK, Gnant M, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR


104

5,991IF:

Chirurgische Onkologie an der Jahrtausendwende - Editorial

Gnant M


105

0,000IF:

Different transendothelial migration behaviour pattern of blood monocytes derived from patients withbenign and malignant diseases of the breast

Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A

Anticancer Res 2000; 4599-604

106

1,416IF:

Heat Treatment of Hepatocellular Carcinoma Cells: Increased Levels of Heat Shock Proteins 70 and90 Correlate with Cellular Necrosis

Schueller G, Paolini P, Friedl J, Stift A, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M

Anticancer Res 2001; 21: 295-300

107

1,416IF:

2


Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients

Locker GJ, Wenzel C, Schmidinger M, Gnant M, Marosi C, Jakesz R, Zielinski CC, Steger G

Anticancer Drugs 2001; 12: 209-12

108

2,013IF:

Evaluation of the United States food and drug administration-approved scoring and test system ofHER-2 protein expression in breast cancer

Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-EckersbergerD, Gnant M, Jakesz R

Clin Cancer Res 2001; 7: 1669-1675

109

5,991IF:

Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer

Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R

Br Cancer Res Treat 2001; 67:1-8

110

2,866IF:

Prognostic Relevance of three histological grading methods in breast cancer

Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G,for the Austrian Breast and Colorectal Cancer Study Group

Int J Oncol 2001; 19: 1271-1277

111

2,330IF:

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellularcarcinoma

Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC

Br J Cancer 2001; 85: 1850-1852

112

3,942IF:

Polychemotherapy for early breast cancer: an overview of the randomised trials with quality-adjustedsurvival analysis

Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A, for the EBCTCG

Lancet 1998; 358: 277-286

113

11,793IF:

Combined analysis of two phase II trials in patients wirh primary and advanced breast cancer withepidoxorubicin and docetaxel + G-CSF

Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MFX, Jakesz R, Steger GG

Anti-Cancer Drugs 2002; 13: 67-74

114

2,013IF:

Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma usingtumor lysate-pulsed dendritic cells

Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schueller G, Benkoe T, Niederle B, BrostjanC, Jakesz R, Gnant M

J Clin Endoc Metab 2002; 87: 1098-1104

115

5,447IF:

Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliativetreatment of patients with breast cancer

Wenzel C, Locker G, Pluschnig U, Zielinski C, Rudas M, Oberhuber G, Gnant M, Taucher S, Jakesz R, Steger G

Cancer Chemother Pharmacol 2002; 50: 155-159

116

2,170IF:

2


Overexpression of hypoxia inducible factor (HIF) 1alpha ias associated with an unfavourableprognosis in lymph node-positive breast cancer

Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E Birner P,Oberhuber G

Clin Cancer Res 2002; 8: 1931-1837

117

5,991IF:

A Randomized Trial of Tamoxifen and Goserelin versus CMF: Evidence for the Superiority ofTreatment with Endocrine Blockade in Premenopausal Patients with Hormone-Responsive BreastCancer (ABCSG Trial 5)

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Steger G,Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Wette V, for the Austrian Breast Cancer Study Group

J Clin Oncol 2002; 20: 1-9

118

9,868IF:

Induction of permeability across endothelial cel monolayers by tumor necrosis factor (TNF) accurs viaa tue factor-dependent mechanism: relationship between the procoagulant and permeability effects ofTNF.

Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EM, Gnant M, Alexander HR

Blood 2002; 100: 1334-1339

119

9,631IF:

Stereotactic 11-gauge vacuum assisted breast biopsy: a validation study

Pfarl G, Helbich TH, Riedl CC, Wagner T, Gnant M, Rudas M, Liberman L

AJR 2002; 179: 1503-1507

120

2,424IF:

Pattern of hormone receptor status of secondary contralateral breast cancers in patients receivingadjuvant tamoxifen

Bachleitner-Hofmann T, Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, JakeszR

Clin Cancer Res 2002; 8: 3427-3432

121

5,991IF:

Young age as independent adverse prognostic factor in premenopausal patients with breast cancer

Dubsky PC, Gnant M, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agstner I, Seifert M, Sevelda P, Jakesz R

Clin Breast Cancer 2002; 13: 67-74

122

0,000IF:

Dendritic cell based vaccination in solid organ cancer

Stift A, Friedl J, Brostjan C, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M

J Clin Oncol 2003; 21: 135-142

123

10,864IF:

Sequential steroid hormone receptor measurements in primary breast cancer with and withoutintervening primary chemotherapy

Taucher S, Rudas M, Gnant M, Dubsky P, Roka S, Bachleitner-Hofmann T, Kandioler D, Wenzel C, Steger G, MittlboeckM, Jakesz R

Endo Rel Cancer 2003; 10: 91-98

124

8,894IF:

In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells

Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M

Int J Oncol 2003; 22: 651-660

125

2,536IF:

2


Tamoxifen versus Tamoxifen plus Aminoglutethimid as Adjuvant Treatment in Postmenopausalbreast Cancer Patients wirth Hormone-responsive Disease: A Randomized Trial of 2,021 Patients(ABCSG Trial 6)

Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B,Steindorfer P, Kwasny W, Fridrik M, wette H, Hausmaninger H, for the Austrian Breast Cancer Study Group

J Clin Oncol 2003; 21: 984-990

126

10,864IF:

Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer

Schoppmann S, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner

Int J Cancer 2003; 104: 677-682

127

4,375IF:

Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent foco-culture with tumor lysate pulsed dendritic cells

Schueller G, Stift A, Friedl J, Dugsky P, Bachleitner-Hofmann T, Benkoe T, Jakesz R, Gnant M

Int J Oncol 2003; 22: 1397-1402

128

2,536IF:

Impact of pretreatment thrombocytosis on survival in primary breast cancer

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A,Jakesz R, for the Austrian Breast and colorectal Cancer Study Group

Thromb Haemost 2003; 89: 1098-1106

129

4,950IF:

Exact log rank tests for unequal follow-up

Heinze G, Gnant M, Schemper M

Biometrics 2003; 59: 1151-1157

130

1,324IF:

Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 andBRCA2 gene

Taucher S, Gnant M, Jakesz R

Langenbecks Arch Surg 2003; 388: 3-8

131

0,921IF:

Randomized trial: One cyle of anthracycline-containing adjuvant chemotherapy compared with sixcycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients

Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B,Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H, and the Austrian Breast and Colorectal Cancer StudyGroup

Onkologie 2003: 26: 115-119

132

1,154IF:

Gnant M, Dubsky P, Stift A, Friedl J, Steger G, Jakesz R, Zielinski C

Future Directions in the treatment of Breast Cancer: Celllular interventions using dendritic cells

Breast Canc Res Treatm 2003; 81

133

3,310IF:

Monitoring of circulating angiogenetic factors in dendritic cell-based cancer immunotherapy

Brostjan C, Bayer A, Zommer A, Gornikiewicz S, Roka S, Benkö T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J,Stift A

Cancer 2003; 98: 2291-30

134

4,017IF:

2


The impact of progesterone receptor in prediction of complete pathological response to preoperativechemotherapy in primary breast cancer patients

Taucher S, Rudas M, Gnant M, Dubsky P, Sporn E, Roka S, Bachleitner-Hofmann T, Fitzal F, Kandioler D, Wenzel C,Steger G, Draxler W, Mittlboeck M, Jakesz R

European Surgery 2003;

135

0,000IF:

Pancreatic Cancer Treatment

Gnant M

European Surgery 2003; 35: 342-343

136

0,000IF:

Do we need HER2/neu testing for all patients with primary breast carcinoma?

Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Bachleitner-Hofmann T, Roka S, Fitzal F, Kandioler D, Sporn E, FriedlJ, Mittlboeck M, Jakesz R

Cancer 2003; 98: 2547-2553

137

4,017IF:

Consensus on Medical Treatment of Metastatic Breast Cancer

Beslija S, Bonneterre J, Burstein H, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W, Krainer M, Menard S, MilesD, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, ZielinskiC, Zwierzina H

Br Canc Res Treatm 2003; 81: S1-S7

138

2,964IF:

Influence of neoadjuvant therapy with epirubicin an ddocetaxel on the expression of HER2/neu inpatients with breast cancer

Taucher S, Rudas M, Mader R, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner-Hofmann T, Fitzal F, Kandioler D,Wenzel C, Steger G, Mittlboeck M, Jakesz R

Breast Canc Res Treatm 2003; 82: 207-213

139

2,964IF:

Significant Increase in breast conservation in 16 years of clinical trials conducted by the AustrianBreast & Colorectal Cancer Study Group

Jakesz R, Hausmaninger H, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, MenzelRC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Seifert M, and the Austrian Breast & Colorectal Cancer Study Group(ABCSG)

Ann Surg 2003; 237: 556-564

140

6,664IF:

Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellularcarcinoma in vivo

Schueller G, Kettenbach J, Sedivy R, Stift A, Friedl J, Gnant M, Lammer J

Int J Oncol 2004; 24:609-13

141

3,056IF:

Gastrointestinal Autonomic Nerve Tumors: A surgical point of view

Stift A, Friedl J, Gnant M, Herbst F, Jakesz R, Wenzl E

World J Gastroenterology 2004; 10: 2447-2451

142

3,318IF:

Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer

Schoppmann S, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M,Jakesz R, Horvat R, and the Austrian Breast and colorectal Cancer Study Group

Annals Surg 2004; 204: 306-312

143

5,907IF:

2


Dendritic cell vaccination in medullary thyroid carcinoma

Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J

Clin Cancer Res 2004; 10:2944-2953

144

5,623IF:

Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325primary breast cancer patients

Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Roka S, Bachleitner-Hofmann T, Kandioler D, Steger G, Mittlboeck M,Jakesz R

Wien Klin Wochenschr 2004; 116:26-31

145

0,901IF:

Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primarybreast cancer: a pilot study

Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M, Gnant M, Jakesz R, Zielinski C, Steger G


146

2,409IF:

Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation inan animal model

Schueller G, Kettenbach J, Sedivy R, Bergmeister H, Stift A, Friedl J, Gnant M, Lammer J

Oncology Rep 2004; 12: 495-499

147

1,356IF:

High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS

Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R

Eur J Surg Oncol 2004; 30; 243-247

148

1,882IF:

A prospective randomized trial to study the role of levamisole and interferon alfa in an adjuvanttheapy with 5-FU for stage-III colon cancer

Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, MischingerHJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R, for the ABCSG

Br J Cancer 2005; 92: 1655-62

149

4,115IF:

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-yearsurvival: an overview of the randomised trials

Early Breast Cancer Trialists Collaborative Group (EBCTCG)

Lancet 2005; 365: 1687-1717

150

23,878IF:

Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellularcarcinoma treated by liver transplantation?

Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, Steininger R, Muehlbacher F

Am J Transplant 2005; 5: 788-94

151

6,002IF:

Preoperative chemotherapy with epidoxorubicin, docetaxel, and capecitabine plus pegfilgrastim inpatients with primary breast cancer

Wenzel C, Bartsch R, Locker GH, Hussian D, Pluschnig D, Sevelda U, Gnant M, Jakesz R, Zielinski C, Steger GG

Anticancer Drugs 2005; 16: 441-5

152

2,052IF:

2


Medullary thyroid carcinoma: autologous tumor cell lins for dendritic cell vaccination

Pfragner R, Skofitsch G, Hoger H, Jech M, Rinner B, Siegl V, Niederle B, Gnant M, Friedl J, Stift A

Anticancer Res 2005; 25:4225-30

153

1,604IF:

Retroviral targeting of proliferating endothelial cells

Gornikiewicz A, Zommer A, Jakesz R, Gnant M, Brostjan C

Acta Biochim Pol 2005; 52: 731-5

154

1,863IF:

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozoleafter 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M,Gademann G, Kaufmann M, for the ABCSG and the GABG

Lancet 2005; 366: 455-62

155

23,887IF:

Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation andfunction of dendritic cells

Dubsky P, Friedl J, Stift A, Bachleitner-Hofmann T, Jakesz R, Gnant M, Weigel G

Clin Chim Acta 2006; 364: 139-47

156

2,328IF:

Bisphosphonates and the prevention of osteoporosis in the adjuvant setting

Gnant M

Breast Cancer Online 2005; Nov; 1-3, e55

157

0,000IF:

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C,Cameron D, Dowsett M, Barrios C, Steger G, Huang C, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H,Thomssen C, Lohrisch C, Suter T, Rüschoff J, Sütö T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci M, Gelber R,

N Eng J Med 2005; 353: 1659-72

158

44,016IF:

Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centerexperience

Steger G, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker G, Gnant M, Jakesz R, Zielinski C

Eur J Cancer 2005; 41: 2655-61

159

3,706IF:

Effects of radiotherapy and of differences in the extend of surgery for early breast cancer on localrecurrence and on 15-year survival: an overview of the randomised trials

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E,McGale P, McHugh T, Peto R, Taylor C, Wang Y and the Early Breast Cancer Trialists Collaborative Group (EBCTCG)

Lancet 2005; 366: 2087-106

160

23,878IF:

Preoperative second-line chemotherapy induces objective responses in primary breast cancer

Wenzel C, Locker G, Bartsch R, Pluschnig U, Hussian D, Zielinski CC, Rudas M, Gnant M, Jakesz R, Steger GG


161

0,901IF:

2


Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients

Fitzal F, Sporn E, Draxler W, Mittlboeck M, Taucher S, Rudas M, Roedl O, Helbich T, Jakesz R, Gnant M

Breast Cancer Res Treatm 2006; 97: 9-15

162

4,671IF:

Aetiology and surgical management of toxic megacolon

Ausch C, Maddoff RD, Gnant M, Rosen HR, Garcia-Aguilar J, Hoelbling N, Herbst F, Buxhofer V, Holzer B, RothenbergerDA, Schiessel R

Int J Colorectal Disease 2006; 8: 195-201

163

2,006IF:

Surgical Oncology - a proud speciality

Gnant M

European Surgery 2006; 38/1: 2-3

164

0,000IF:

The endocrine origin and different characters of breast cancers - recent research on hormonereceptors and endocrine treatment

Dubsky P, Gnant M

Breast Care 2006; 1: 124-8

165

0,242IF:

VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact onlymphangiogenesis and survival

Schoppmann S, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvath R, Jakesz R, Birner P

Surgery 2006; 139: 839-46

166

2,977IF:

Management of bone loss induced by aromatase inhibitors

Gnant M

Cancer Invest 2006; 24: 328-30

167

2,335IF:

Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breastcancer

Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P

Breast Cancer Res Treat 2006; 99: 135-41

168

4,671IF:

Breast conservation: evolution of surgical strategies

Fitzal F, Gnant M

Breast 2006; 12S2: 165-73

169

1,705IF:

Breast Centers Revisited - a critical perspective

Gnant M

Breast Care 2006; 1: 150-1

170

0,242IF:

2


Multidetector CT of Pancreas_ Effects of Contrast Material Flow Rate and Individualized Scan Delayon Enhancement of Pancreas and Tumor Contrast

Schueller G, Schima W, Schueller-Weidekamm C, Weber M, Stift A, Gnant M, Prokesch R

Radiology 2006; 241: 441-8

171

5,251IF:

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women withhormone-sensitive early-stage breast cancer: a meta-analysis

Gnant M, Jonat W, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R

Lancet Oncology 2006; 7: 991-996

172

10,119IF:

Heat shock treatment of tumor lysat-pusled DCs enhances their capacity to elicit antitumor T-cellresponses against medullary thyroid carcinoma

Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, Schoppmann S, Pfragner R, GnantM, Friedl J, Stift A

J Clin Endocrinol Metab 2006; 91: 4571-7

173

5,799IF:

Breast Cancer Chemoprevention - not yet there

Gnant M, Blaha P

Breast Care 2006; 1: 295-6

174

0,242IF:

A case of phylloides tumor with focal transition into low-grade lymphangiosarcoma

Bachleitner-Hofmann T, Schoppmann S, Rudas M, Birner P, Wiener H, Dubsky P, Blaha P, Sporn E, Panhofer P, Fitzal F,Roka S, Kandioler D, Gnant M, Jakesz R

Breast Care 2006; 1: 391-4

175

0,242IF:

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response followingneoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF

Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altoraj G, Zielinski CC, Lang A, Hais A, Jakesz R, Gnant M, Steger G

Br Canc Res Treat 2007; 104: 109-14

176

4,453IF:

Breast conserving surgery for T3/T4 breast cancer: an analysis of 196 patients

Fitzal F, Riedl O, Wutzl L, Draxler W, Rudas M, Pluschnig U, Handl-Zeller L, Dubsky P, Bachleitner-Hofmann T, Steger G,Jakesz R, Gnant M


177

4,453IF:

Second Consensus on Medical Treatment of Metastatic Breast Cancer

Beslija S, Bonneterre J, Bustein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M,Menard S, Miles D, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, WilckenN, Wiltschke C, Zielinski C, Zwierzina H

Ann Oncol 2007; 18:215-25

178

4,875IF:

Zoledronic Acid effectively prevents Cancer treatment-induced bone loss in premnopausal womenreceiving adjuvant andocrine therapy for hormone responsive breast cancer

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC,Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, and the ABCSG

J Clin Oncol 2007; 25: 820-8

179

15,484IF:

2


Pathologic complete response with 6 vs. 3 cycles oof Neoadjuvant epirubicin/decetaxel + G-CSF inoperable breast cancer: resutls of ABCSG-14

Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer C, Haid A,Poestlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R, and the ABCSG

J Clin Oncol 2007; 25: 2012-8

180

15,678IF:

The use of a breast symmetry index for objective evaluation of breastcosmesis

Fitzal F, Krois W, Trischler H, Wutzel L, Riedl O, Kühbelböck U, Wintersteiner B, Cardoso MJ, Dubsky P, Gnant M, JakeszR, Wild T

Breast 2007;4:429-35

181

1,739IF:

Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated withpoor outcome in node-negative breast cancer

Schindl M, Gnant M, Schoppmann S, Horvat R, Birner P


182

1,414IF:

Managing aromatase inhibitor-associated bone loss in breast cancer

Lipton A, Gnant M, Aapro M

Womans Health 2007; 3:441-448

183

0,000IF:

Extended adjuvant therapy with Anastrozole among postmenopausal breast cancer patients: Resultsfrom the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K,Dadak C, Ruecklinger E, Samonigg H, on behalf of the ABCSG

J Natl Canc Inst 2007; 99:1845-53

184

15,678IF:

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausalpatients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data fromrandomised adjuvant trials

LHRH-agonists in Early Breast Cancer Overview Group

Lancet 2007; 369: 1711-23

185

28,638IF:

Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial

Suter T, Procter M, van Veldhuisen D, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn J,Ageev F, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber R, Piccart-Gebhart M

J Clin Oncol 2007; 25:3859-65

186

15,484IF:

Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women withfavourable early breast cancer

Poetter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G,Schmid M, Sedlmayer F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Poestlberger S, Haider K, Draxler W,Jakesz R; on behaslf of the ABCSG

Int J Radiat Oncol 2007; 68: 334-40

187

4,290IF:

Novel strategies in oncoplastic surgery for breast cancer: immediate partial reconstruction of breastdefects

Fitzal F, Nehrer G, Deutinger M, Jakesz R, Gnant M

Eur Surg 2007; 39:330-39

188

0,000IF:

2


Capecitabine and Trastuzumab in heavily preatreated patients with metastatic breast Cancer

Bartsch G, Wenzel C, Altoraj F, Pluschnig U, Rudas M, Mader R, Gnant M, Zielinski C, Steger G

J Clin Oncol 2007; 25: 3853-8

189

15,484IF:

An oncoplastic procedure for central and medio-cranial breast cancer

Fitzal F, Nehrer G, Hoch D, Riedl O, Gutharc S, Deutinger M, Jakesz R, Gnant M

Eur J Surg Oncol 2007; 33: 1158-63

190

3,917IF:

HER-2 and progesterone receptor are not predictive of response to fulvestrant treatment

Bartsch T, Wenzel C, Altrofaj G, Pluschnig U, Mader R, Gnant M, Jakesz R, Rudas M, Zielinski C, Steger G


191

6,250IF:

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: arandomised controlled trial

Smith I, Procter M, Gelber R, Guillaume S, Teyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J,Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardlay A, Harbeck N, Lopez R, Mallmann P, Gelmon K, WilckenN, Wist E, Rovira P, Piccart-Gebhart M, for the HERA study team

Lancet 2007; 369: 29-36

192

28,638IF:

A prospective randomized phase III trial of adjuvant chemotherapy with 5-fuorouracil and leucovorinin patients with stage II colon cancer

Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thodtmann R, Tschmelitsch J, Jagoditsch M, Steger G, Jakesz R,Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, for the ABCSG

Br J Cancer 2007; 97(8):1021-7

193

4,635IF:

Allogenic tumor lysate can serve as both antigen source and protein supplementation for dendriticcell culture

Dubsky P, Hayder H, Sachet M, Bachleitner-Hofmann T, Hassler M, Pfragner R, Gnant M, Stift A, Friedl J

Cancer Immunol Immunother 2008;57(6):859-70

194

3,728IF:

The potential risk of neoadjuvant chemotherapy in breast cancer patients - results from a prospectiverandomised trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)

Taucher S, Steger G, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Bartsch R, Dubsky P,Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M


195

4,453IF:

Guidance on the use of bisphosphonates in solid tumours: recommendations of an internationalexpert panel

Aapro M, Abrahamsson P, Body J, Coleman R, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P,Hortobagyi G, Jonat W, Lipton A, Monnier A, Paterson A, Rizzoli R, Saad F, Thuerlimann B

Annals of Oncology 2008; 19: 420-32

196

4,875IF:

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastaticbreast cancer

Bartsch R, Welzel C, Gampenrieder S, Pluschnig U, Altoraj G, Rudas M, Mader R, Dubsky P, Rottenfusser A, Gnant M,Zielinski C, Steger G


197

2,568IF:

2


Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma

Stadler G, Wieser M, Streubel B, Stift A, Friedl J, Gnant M, Niederle B, Katinger H, Pfragner R, Grillari J, Voglauer R

Eur J Cancer 2008; 44: 866-75

198

4,454IF:

Cyclin D1 expression in breast cancer and tamoxifen therapy

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, GrillR, Stierer M, Gnant M, Filipits M, for the ABCSG

Clin Cancer Res 2008; 14: 1767-74

199

6,250IF:

The localization of small tumor deposits in the SLN predicts Non-SLN macrometastases in breastcancer patients

Li J, Haensch W, Rudas M, Kemmer W, Warnick P, Fischer J, Gnant M, Schlag PM, Bembenek A

Eur J Surg Oncol 2008; 34: 857-862

200

3,917IF:

Adjuvant chemotherapy in oestrogen-receptor-poor early breast cancer: patient-level meta-analysisof randomised trials

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Lancet 2008; 371: 29-40

201

28,638IF:

Exemestane as primary systemic treatment for hormone receptor positive postmenopausal breastcancer patients: a phase II trial opf the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, UrbaniaA, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R, on behalf of the ABCSG


202

4,453IF:

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primarybreast cancer patients receiving adjuvant CMF chemotherapy

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Desnison U, Mlineritsch B, Steger G, KwansyW, Stoeger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Poetter R, Gnant M

Clin Cancer Res 2008; 14: 2082-7.

203

6,250IF:

Moderne Tumortherapie des Pankreaskarzinoms

Sahora K, Trenkwitz D, Akan B, Kuehrer I, Goetzinger P, Gnant M

J Gastroenterol Hepatol Erkr 2008; 6: 17-24

204

0,000IF:

Is risk of central nervous system (CNS)-relaps related to adjuvant taxane treatment in node-positivebreast cancer? Results of the CNS-substudy in the Intergroup phase III BIG 02-98 trial

Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B,Gnant M, Gutierrez J, Lang I, Crown JPA, Piccart-Gebhart M, on behalf of the BIG 02-98 Collaborative Group

Ann Oncol 2008; 19: 1837-41

205

5,179IF:

Neoadjuvante Therapie des Pankreaskarzinoms

Sahora K, Akan B, Kuehrer I, Goetzinger P, Gnant M


206

0,885IF:

2


(Neo-)Adjuvant Chemotherapy in Breast Cancer - Trials, errors and new Rationales from the SABCS2007

Dubsky P, Gnant M

memo 2008; 1: 23-36

207

0,000IF:

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breastcancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kaessmann H, Piswanger-Soelkner C, Seifert M,Schippinger W, Menzel C, Dubsky P, Fitzal F, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Jakesz R, on behalf ofthe ABCSG

Lancet Oncology 2008; 9:840-9.

208

12,274IF:

Breast-conserving therapy for centrally located breast cancer

Fitzal F, Mittlboeck M, Trischler H, Krois W, Nehrer G, Deutinger M, Jakesz R, Gnant M

Ann Surg 2008; 247: 470-6

209

7,446IF:

Adjuvant endocrine Therapy in premenopausal women with breast cancer

Gnant M, Dubsky P, Fitzal F, Steger G, Jakesz R

Breast Care 2008; 3: 311-6

210

0,242IF:

Einsatz von Erythropoease-stimulierenden Proteinen bei anämischen Patienten mit malignenErkrankungen

Ludwig H, Auberger T, Burghuber O, Gnant M, Hopfinger G, Jaeger U, Keil F, Kornek G, Linkesch W, Petrau E, Pirker R,Pittermann E, Reinthaller A, Samonigg H, Steger G, Stockenhuber F, Studnicky M, Weiss G, Zielinski C


211

1,000IF:

Adjuvant endocrine therapy plus zoledronic acid in premenopausal breast cancer

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista E, Marth C,Greil R, on Behalf of the ABCSG

New Engl J Med 2009; 360:679-91

212

52,589IF:

Intraoperative frozen section analysis for breast conservingt therapy in 1.016 patients with breastcancer

Riedl O, Fitzal F, Mader N, Dubsky P, Rudas M, Mittlboeck M, Gnant M, Jakesz R

Eur J Surg Oncol 2009; 35: 264-70

213

3,917IF:

To measure the unmeasurable

Gnant M

World J Surgery 2009; 33: 52-3

214

2,696IF:

Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells

Singer C, Hudelist G, Fuchs E, Koestler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Rudas M, Czerwenka K,Kubista E

Endocrine Rel Cancer 2009; 16: 73-83

215

5,193IF:

2


The evolving role of Zoledronic Acid in early breast cancer

Gnant M

OncoTargets and Therapy 2009; 2: 95-104

216

IF:

Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines inpatients with metastatic medullary thyroid carcinoma

Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R,Brostjan C, Riss S, Niederle B, Gnant M, Stift A

Oncol Rep. 2009; 21:1585-92

217

1,588IF:

Pankreaskarzinom und periampulläres Karzinom

Sahora K, Kührer I, Trenkwitz D, Friedl J, Sautner T, Goetzinger P, Gnant M

J Gastroenterol Hepatol Erkr 2009; 7: 36-46

218

0,669IF:

Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendriticcells for dendritic cell based immunotherapy

Hayden H, Fridl J, Dettke M, Sachet M, Hassler M, Dubsky P, Bachleitner-Hofmann T, Gnant M, Stift A

J Immunoth 2009; 32: 658-64

219

3,203IF:

Breast cancer chemoprevention - a vision not yet realised

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Steger G, Jakesz R, Gnant M

Eur J Cancer Care 2009; 18; 438-46

220

1,038IF:

Bisphosphonates as adjuvant treatment for breast cancer

Gnant M, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Exner R, Blaha P, Jakesz R, Schippinger W, Greil R

Curr Breast Canc Rep 2009; 1: 54-63

221

IF:

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant inpostmenopausal patients with metastatic breast cancer

Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, PoberM, Zielinski CC, Steger GG; on behalf of the Austrian Fulvestrant Registry.


222

4,453IF:

Is endocrine Therapy really pleasant? Considerations about the long-term use of antihormonaltherapy and its benefit/side effect ratio

Blaha P, Exner R, Dal Borgo A, Bigenzahn S, Panhofer P, Riedl O, Schoppmann S, Bachleitner-Hofmann T, Sporn E,Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M

Breast Care 2009; 4:155-61

223

0,500IF:

New results from the use of bisphosphonates in cancer patients.

Coleman R, Gnant M

Curr Opin Support Palliat Care 2009; 3: 213-8

224

2,073IF:

2


Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primarytherapy of early breast cancer 2009.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.

Ann Oncol 2009; 20:1319-29

225

5,647IF:

Third Consensus on Medical Treatment of Metastatic Breast Cancer

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M,Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C,Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; for the Central European Cooperative Oncology Group

Ann Oncol 2009; 20: 1771-85

226

5,647IF:

Maintaining Bone Density in patients undergoing treatment for breast cancer: is there an adjuvantbenefit?

Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann SF, Steger G, Marth C, Samonigg H, Huettner K, Fohler H,Ruecklinger E, Jakesz R, Greil R, on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Clin Breast Cancer 2009; 9: s18-27

227

2,065IF:

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positivebreast cancer patients receiving adjuvant tamoxifen therapy

Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W,Nader A, Stierer M, Gnant M

Clin Cancer Res 2009; 15: 5888-94

228

6,747IF:

Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials

Gnant M

Curr Cancer Drug Targets 2009; 9: 824-33

229

5,385IF:

Cystic neoplasms of the pancreas: Conservative or operative treatment?

Akan B, Sahora K, Puhalla H, Gnant M, Jakesz R, Goetzinger P

Eur Surg 2009; 40:220-6

230

0,629IF:

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

Gnant M, Blaha P, Dubsky P, Exner R, Fitzal F, Sporn E, Panhofer P, DalBorgo A, Bigenzahn S, Jakesz R, Steger G

Ther Adv Med Oncol 2009; 1: 123-36

231

IF:

Adjuvant endocrine therapy in premenopausal women with breast cancer

Gnant M

BCO 2009; 12 (5): 1-8 (e8)

232

0,000IF:

Predicting for activity of second-line trastuzumab-based therapy in HER2-positive advanced breastcancer

Bartsch R, DeVries C, Pluschnig U, Dubsky P, Horvath Z, Gampenrieder S, Rudas M, Mader R, Rottenfusser A, WiltschkeC, Gnant M, Zielinski CC, Steger GG

Br J Cancer 2009; 9: 367

233

4,346IF:

2


Fighting overtreatment in adjuvant breast cancer therapy

Gnant M, Steger GG

Lancet 2009; 374: 2029-30

234

30,758IF:

Bisphosphonates in the adjuvant treatment of early breast cancer

Gnant M

Breast Cancer Res 2009; 11: S17

235

4,696IF:

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleaoni M, Coombes C,Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R, for the Aromatase InhibitorOverview Group

J Clin Oncol 2010; 28: 509-18

236

18,970IF:

Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendation from anInternational Expert Panel

Kaufmann M, von Mickwitz G, Morrow M, The Biedenkopf Expert Panel Members

Cancer 2010; 116: 1184-9

237

5,131IF:

The anti-tumor effect of bisphosphonates: ABCSG-12, ZO-FAST and more...

Gnant M, Eidtmann H

Crit Rev Onc Hem 2010; 74: S2-6

238

4,589IF:

Mammakarzinom: Bisphosphonate in der Adjuvanz - auch aus gesundheitsökonomischer Sicht einesinnvolle Therapie

Lux MP, Nowitzki C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M

Geburtsh Frauenheilk 2010; 70: 8-11

239

0,342IF:

Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women withHormone-Responsive Early Breast Cancer

Delea T, Taneja C, Sofrygin O, Kaura S, Gnant M

Clin Breast Cancer 2010; 4: 267-74

240

2,790IF:

The evolution of bone-targeted therapies: Introduction

Gnant M

Sem Oncol 2010; 37: S1

241

3,355IF:

Results of the Zometa® Cost-utility model for the German healthcare system based omn the resultsof the ABCSG-12 study

Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M

Onkologie 2010; 33: 360-8

242

1,153IF:

2


Neue Studiendaten zur endokrinen Langzeittherapie

Gnant M

Gyn Spectrum 2010; 1: 4-6

243

0,000IF:

Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vitroprocesses

Starlinger P, Moll H, Assinger A, Nemeth C, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann S, Gnant M, BrostjanC

J Thromb Hemosta 2010; 8: 1809-19

244

4,701IF:

Can oral bisphophonates really reduce the risk of breast cancer in healthy women?

Gnant M

J Clin Oncol 2010; 28: 3548-51

245

18,970IF:

Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced andmetastatic breast cancer

Gampenrieder S, Bartsch R, Scheuer R, Pluschnig U, Dubsky P, Gnant M, Zielinski C, Steger G

Breast Care 2010; 5: 158-162

246

0,364IF:

Neoadjuvant Treatment and Breast Conserving Surgery - a success of clinical research in breastcancer

Gnant M

Wien Med Wochenschr 2010; 160: 163-6

247

0,000IF:

Overview of the ransomized trials of radiotherapy in ductal carcinoma in situ of the breast

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C,Peto R, Bijker N, Solin L, Darby S

J Natl Cancer Inst Monogr 2010; 41: 162-77

248

14,697IF:

Closing in on the unknown enemy

Gnant M, Dubsky PC

Lancet Oncol 2010; 11:402-3

249

17,764IF:

Breast Cancer: Rank Ligand Inhibition

Bartsch R, Steger G, Gnant M, Ziebermayr R

Breast Care 2010; 5: 320-325

250

0,364IF:

HER-2/neu-expression correlates with vascular endothelial growth factor-C and lymphangiogenesisin llymph node positive breast cancer

Schoppmann S,Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P

Ann Oncol 2010; 21: 955-60

251

6,452IF:

2


Potential anticancer properties of bisphosphonates

Neville-Webbe H, Gnant M, Coleman R

Semin Oncol 2010; 7: S53-65

252

3,355IF:

Use of aromatase inhibitors and bisphosphonates as an anti-cancer therapy in postmenopausalbreast cancer

Mouridsen H, Lonning P, Beckmann M, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B,Gnant M

Expert Rev Anticancer Ther 2010; 11: 1825-36

253

2,976IF:

Prevention of bone metastases and management of bone health in early breast cancer

Gnant M, Hadji P

Breast Cancer Research 2010; 12: 216

254

4,859IF:

Modulation of plasma complement by the initial dose of epirubicin / docetaxwl therapy in breastcancer and its predictive value

Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-DeschmannM , Rech-Weichselbraun I, Burghuber C,Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R

Br J Cancer 2010; 103: 1201-8

255

4,831IF:

10 years of ATAC: one question answered, many others unresolved

Gnant M

Lancet Oncology 2010; 11: 1109-10

256

17,764IF:

Adjuvant Bisphosphonate therapy in postmenopausal breast cancer patients

Gnant M

Breast Care 2010; 5: 298-304

257

0,364IF:

Dosing of Zoledronic Acid throughout the treatment continuum in breast cancer

Hadji P, Gnant M, Aapro M, Lipton A, Coleman R

Crit Rev Oncol Hematol 2011; 79:175-88

258

4,411IF:

Sentinel Node Biopsy after primary chemotherapy in breast cancer: A note of caution from resultsfrom ABCSG-14

Tausch C, Steger G, Haid A, Jakesz R, Fridrik M, Reitsamer R, Poestlberger S, Lang A, Gnant M, Greil R, on behalf of theABCSG

Breast J 2011; 17: 230-8

259

1,643IF:

Adjuvant Zoledronic Acid reduces disease recurrence in breast cancer:Antitumor effects on the seed and the soil

Gnant M

Curr Cancer Ther Rev 2011; 7: 111-18

260

IF:

2


Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy betweenchemotherapy and anti-VEGF treatment

Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C

Neoplasia 2011; 13; 5: 419-27

261

5,946IF:

Lipoxigenase mediates Invasion of intrametastatic lymphatic vessels and propagates lymph nodemetastasis of human mammary carcinoma xenografts in mouse

Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Wolbank S, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R,Hantusch B, Keller T, Nagy-Bojarski K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S,Madlener S, Vonach C, Davidovits A, Nosaka H, Haemmerle M, Viola K, Dolznig H, Schreiber M, Nader A, Mikulits W,

J Clin Invest 2011; 132: 2000-12

262

13,069IF:

NeoGemTax - Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced non-metatasized pancreatic cancer

Sahora K, Kuehrer I, Fitzal F, Schindl M, Koelblinger C, Goetzinger P, Gnant M

World J Surg 2011; 35: 1580-9

263

2,362IF:

Intravenous bisphosphonates for breast cancer: Impact on patient outcomes and scientific concepts

Gnant M

Breast Disease 2011; 33: 71-81

264

IF:

Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts

Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann S, Gnant M, Brostjan C

Disease Markers 2011; 31: 55-65

265

1,642IF:

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early breast cancer:62-month follow-up from ABCSG-12

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengruth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G,Bauernhofer T, Eidtmann H, Eiermann W., Steger G, Kwasny W, Dubsky P, Hochreiner G,, Forsthuber EP, Fesl C, Greil R,on behalf of the ABCSG

Lancet Oncol 2011; 12: 631-41

266

22,589IF:

A new molecular predictor of distant recurrence in estrogen recpetor-positive HER2-negative breastcancer adds independent information to conventional clinical risk factors

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer C, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V,Jänicke F, Schmidt M, Kölbl H, Rody A, kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS,Henning G, Gehrmann M, Gnant M

Clin Cancer Res 2011; 17: 6012-20

267

7,742IF:

Zoledronic Acid in Breast Cancer: Latest Findings and Interpretations

Gnant M

Ther Adv Med Oncol 2011; 3: 293-301

268

IF:

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thuerlimann B, Senn HJ, & Panel members

Ann Oncol 2011; 22: 1736-47

269

6,425IF:

2


St. Gallen 2011: Summary of the consensus discussion

Gnant M, Harbeck N, Thomssen C

Breast Care 2011; 6: 136-41

270

0,446IF:

Oncologic safety of breast conserving surgery after tumor downsizing by neoadjuvant therapy: Aretrospective single centre cohort study

Fitzal F, Riedl O, Mittlboeck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M


271

4,431IF:

Preoperative oxaliplatin, capecitabine and external beam readiotherapy in patients with newlydiagnosed, primary operable, cT3NxM0 low rectal cancer - a Phase II study

Öfner D, DeVries A, Schaberl-Mosef R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp K, Fastner G, Keil F, Eisterer W,Jäger R, Offner F, Gnant M, Thaler J, for the TAKO 05/!BCSG R02 Trial Investigators

Strahlenther Oncol 2011; 187: 100-7

272

3,561IF:

Relevance of breast hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Lancet 2011; 378: 771-84

273

38,278IF:

Developing an international network for breast cancer research: the Breast International Group (BIG)experience

Gnant M, Piccart-Gebhart M, Goldhirsch A, Baselga J, Cameron D, Di Leo A, Dowsett M, Gelber M, von Mickwitz G,Wadvogel C, Straehle C

Clin Invest 2011; 1(5): 623-28

274

13,069IF:

Discrimination between circulating endothelial cells and blood cell populations with overlappingphenotype reveals distinct regulation and predictive potential in cancer therapy

Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C

Neoplasia 2011; 13: 980-90

275

5,946IF:

Impact of Body Mass Index on the efficacy of endocrine therapy in premenopausal patients withbreast cancer: An analysis of the prospective ABCSG-12 trial

Pfeiler G, Koenigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer C, Poestlberger S, Steger G, Seifert M, Dubsky P,Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M

J Clin Oncol 2011; 29: 2653-9

276

18,372IF:

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breastcancer: Practical guidance for prevention and treatment

Hadji P, Aapro M, Body J, Bundred N, Brufsky A, Coleman R, Gnant M, Guise T, Lipton A

Annals of Oncology 2011; 22: 2546-55

277

6,425IF:

Targeted therapies: Adjuvant bisphosphonates - an option with low estrogen?

Gnant M

Nature Reviews Clinical Oncology 2011; 8: 698-9

278

11,963IF:

2


Pregnancy after breast cancer: if you wish, ma'am

Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A; Breast International Group; NorthAmerican Breast Cancer Group Endocrine Working Group


279

4,431IF:

NeoGemOx - Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced non-metastasized pancreatic cancer

Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Pecl-Radosavlejvid M,Ba'ssalamah A, Zielinski C, Gnant M

Surgery 2011; 143: 311-20

280

3,103IF:

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breastcancer mortality in women with early breast cancer: analysis of individual patient data on 10,801women in 17 randomised trials


Lancet 2011; 378: 1707-16

281

38,278IF:

Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausalwomen with low proliferating breast cancer

Bago-Horvath Z, Rudas M, Dubsky P, Singer C, Dietze O, Greil R, Jelen A, Boehm G, Jasarevic Z, Lang A, Gruber C,Poestlberger S, Filipits M, Gnant M, on behalf of the ABCSG

Clin Cancer Res 2011;17: 7828-34

282

7,742IF:

Bisphosphonates in the adjuvant treatment of breast cancer - Rationale and clinical data

Gnant M

Clin Invest 2011; 1: 97-107

283

13,069IF:

Impact of anti-HER2 therapy on overall survival in HER2-positive metastatic breast cancer patientswith brain metastases

Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, DieckmannK, Mader R, Gnant M, Zielinski C, Steger G

Br J Cancer 2012; 106: 25-31

284

5,082IF:

Dual HER2 inhibition in breast cancer treatment

Gnant M, Steger GG

Lancet 2012; 379; 596-8

285

39,060IF:

Results of the first Austrian multidisciplinary expert panel on controversies in local treatment of breastcancer

Knauer M, Gnant M, Fitzal F, Panel Members

Breast Care 2012; 7: 61-66

286

0,680IF:

Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, andLymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast andColorectal Cancer Study Group (ABCSG)

Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, GnantM

Ann Surg Oncol 2012; 19: 1808-17

287

4,166IF:

2


Zoledronic Acid in the treatment of early stage breast cancer: Is there a final verdict?

Gnant M

Curr Oncol Reports 2012; 14:35–43

288

3,327IF:

Recommendations from an International Consensus Conference on the Current Status and Future ofNeoadjuvant Systemic Therapy in Primary Breast Cancer

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M,Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L

Ann Surg Oncol 2012; 19: 1508-16

289

4,166IF:

Antiresorptive treatment options and bone health in cancer patients - safety profile and clinicalconsiderations

Hadji P, Aapro M, Costa L, Gnant M

Cancer Treatm Rev 2012; 38, 815-24

290

6,054IF:

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Baselga J, Campone M, Piccart M, Burris HA, Rugo, HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, BeckJT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu C, Mukhopadhyay P, Lebwohl D, Hortobagyi GN

N Eng J Med 2012; 366: 520-9

291

53,298IF:

Objetively measured breast symmetry has no influence on quality of life in breast cancer patients

Exner R, Krois W, Mittlböck M, Dubsky P, Jakesz R, Gnant M, Fitzal F

Eur J Surg Oncol 2012; 38: 130-6

292

2,614IF:

Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locallyadvanced rectal cancer - A two stage phase II clinical trial

Resch G, DeVries A, Oefner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J, on behalb of the ABCSG

Radiother Oncol 2012; 102: 10-3

293

5,580IF:

Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?

Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise T, Lipton A, Aapro MS

Cancer Treatm Rev 2012; 38: 798-806

294

6,054IF:

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analysesof long-term outcome among 100 000 women in 123 randomised trials


Lancet 2012; 379: 432-44

295

39,060IF:

Bisphosphonates: prevention of bone metastases in breast cancer

Gnant M, Dubsky P, Hadji P

Recent Results Cancer Res. 2012;192:65-91

296

2,000IF:

2


The sequential use of endocrine treatment for advanced breast cancer: where are we?

Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Guzudar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C,Robertson J

Ann Oncol 2012; 23: 1378-86

297

7,384IF:

Neoadjuvant chemotherapy increases the rate of breast conservation on lobular-type breast cancerpatients

Fitzal F, Mittlboeck M, Steger G, Bartsch G, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M

Ann Surg Oncol 2012; 19: 519-26

298

4,166IF:

Taxoxifen and Anastrozole as a sequencing strategy: A randomized controlled trial inpostmenopausal patients with endocrine-responsive early breast cancer: Final results from theAustrian Breast and Colorectal Cancer Study Group

Dubsky P, Jakesz R, Mlineritsch B, Poestlberger, Graz2, Kwasny W, Tausch C, Samonigg H, Haider K, Fitzal F, Singer C,Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger G, Greil R, Filipcic L, Gnant M, onbehalf of the ABCSG

J Clin Oncol 2012; 30: 722-8

299

18,372IF:

Anticancer activity of bisphosphonates in breast cancer

Gnant M

Anticancer Agents Med Chem 2012; 12: 114-22

300

3,144IF:

Brain metastases free survival differs between breast cancer subtypes

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F,Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Br J Cancer 2012; 106: 440-6

301

5,082IF:

Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasivebreast cancer

Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Fitzal F, Dubsky P, Jesch B, Birner P


302

4,469IF:

Treatment of bone metastases in patients with advanced breast cancer

Gnant M, Balic M, Petru E, Raunik W, Singer CF, Steger GG, Watzke IM, Brodowicz T

Breast Care 2012; 7: 92-8

303

0,680IF:

Bone Targeted Agents: Effects on disease progression and mortality in solid tumour andhaematological cancers

Coleman RE, Gnant M, Morgan G, Clezardin P

J Nat Cancer Inst 2012; 104: 1059-1067

304

14,700IF:

Overcoming endocrine resistance in breast cancer: importance of mammalian target of rapamycin(mTOR) inhibition

Gnant M

Expert Rev of Anticancer Ther 2012; 12: 1579-89

305

2,652IF:

2


Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women withmetastatic breast cancer

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F,Gnant M, Zielinski CC, Steger GG

Eur J Cancer 2012; 48: 1932-8

306

5,061IF:

The impact of menopause on bone and implications for breast cancer growth and metastasis

Hadji P, Coleman R, Gnant M, Green J

Ann Oncol 2012; 23: 2782-90

307

7,384IF:

Direct and indirect Anticancer Activity of Bisphosphonates: A review of published literature

Gnant M, Clezardin P


308

6,054IF:

Axilladissektion bei positivem Sentinel-Lymphknoten - Ergebnisse Innsbrucker Konsuskonferenz

Hubalek M, Gnant M, Bartsch R, Kapp K, Lang A, Lax S, Lukas P, Neunteufel W, Reitsamer R, Sandbichler P, Schrenk P,Tamussino K, Pristauz G, Tschmelitsch J, Singer C, Zeimet A, Marth C

Geburtsh Frauenheilk 2012; 72:299–304

309

0,848IF:

8th European Breast Cancer Conference (EBCC-8)

Gnant M, Beermann B

Breast Care 2012; 7: 170-6

310

0,680IF:

Adjuvant bisphosphonates: a new standard of care?

Gnant M

Curr Opin Oncol 2012, 24:635-42

311

4,101IF:

Entwicklungen der forschenden Pharmaindustrie

Thomssen C, Gnant M, Harbeck N

Breast Care 2012; 7: 155-64

312

0,680IF:

Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.

Arnold T, Micklmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R

Eur J Clin Invest 2013; 43:286-91

313

3,365IF:

The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of AdvancedBreast Cancer

Gnant M

Curr Oncol Rep 2013; 15: 14-23

314

2,545IF:

2


EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D,Schmidt M, Gehrmann M, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M

Ann Oncol 2013; 24:640-7

315

7,384IF:

Health-related quality of life and disease symptoms in postmenopausal women with advanced breastcancer treated with everolimus plus exemestane versus exemestane monotherapy

Campone M, Lebrun F, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M,Hortobagyi GN, Nunzi M, Heng D, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J,Cahana A, Taran T, Sahmoud T, Burris HA

Curr Med Res Opinion 2013; 24: 2206-23

316

2,380IF:

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatmentwith anastrozole in postmenopausal patients with breast cancer - an analysis of the randomizedABCSG 6a trial

Gnant M, Pfeiler G, Stoeger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, StegerG, Samonigg H, Fesl C, Jakesz R, on behalf of the ABCSG

Brit J Cancer 2013; 109: 589-96

317

5,061IF:

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil T, Dietze O, Luisser I, Klug E, Sedivy R, Bachner R, Mayr D,Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M, on behalf of the ABCSG

Br J Cancer 2013; 109: 2959-64

318

5,082IF:

Microparticle-associated tissue factor activity in patients with pancreatic cancer: Correlation withclinicopathological features

Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Müllauer L, Gnant M, Scheithauer W, Pabinger I

Eur J Clin Invest 2013; 43: 277-85

319

3,365IF:

St. Gallen 2013: Brief preliminary summary of the Consensus discussion

Harbeck N, Thomssen C, Gnant M

Breast Care 2013; 8: 102-9

320

0,911IF:

Health-related Quality of Life of Advanced Breeast Cancer Patierns treated with Everolimus plusExemestane versus Placebo plus Exemestane in the Phase 3, randomized, controlled, BOLERO-2trial

Burris HA, Lebrun F, Hugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi G, Komorowski A,Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Rixxi JF, Bauly H, Taran T, Sahmoud T, Noguchi S

Cancer 2013; 119: 1908-15

321

3,662IF:

Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer - Summary andresults of an Austrian Expert Panel discussion

Gnant M, Greil R, Hubalek M, Steger G

Breast Care 2013; 8: 293-9

322

0,911IF:

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patientswith hormone-receptor positive breast cancer – an analysis of 1509 patients of the ABCSG-06 trial

Pfeiler G, Stoeger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U,Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, GreilR, Fesl C, Gnant M, on behalf of the ABCSG

Br J Cancer 2013; 108: 1408-14

323

5,082IF:

2


CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Study Group trial(ABCSG) 8

Goetz M, Suman V, Ames M, Gnant M, Filipits M, Hoskin T, Safgren S, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O,Lang A, Offner F, Reynolds C, Weinshilboum R, Ingle J


324

7,837IF:

Effect of visceral metastases on the efficacy and safety of Everolimus in postmenopausal woem withadvanced breast cancer: subgroup analysis from the BOLERO-2 study

Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L,Burris HA, Hart LL, Melichar B, Hoartobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimi M, TaranT, Sahmoud T, Piccart M

Eur J Cancer 2013; 49: 2621-32

325

5,061IF:

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 finalprogression-free survival analysis.

Yardley DA, Noguchi S, Prichard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Capone M, Pistilli B, Piccart M,Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Fend W, Cahana A, Taran T, Sahmoud T, Lebwohl D, Rugo HS

Adv Ther 2013; 30:870-84

326

2,125IF:

Aromatase inhibitors with or without a gonadotropin-releasing hormone analogue in male breastcancer patients: a case series

Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M,Dimopoulos MA, Bartsch R

Br J Cancer 2013; 108: 2259-63

327

5,082IF:

Personalizing the treatment of women with early breast cancer: highlights of the St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, and Panel Members

Ann Oncol 2013; 24: 2206-23

328

7,384IF:

Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus

Hadji P, Coleman R, Gnant M

Crit Rev Oncol Hematol 2013; 101-11

329

5,270IF:

Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review andMeta-Analysis

Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, MauriD

Oncologist 2013; 18 (4): 353-61

330

4,095IF:

Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive MetastaticBreast Cancer

Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, BartschR

Breast J 2013; 19:149-55

331

1,831IF:

Guidelines: Usefulness and Limitations

Gnant M

Breast Care 2013; 8: 172-173

332

0,911IF:

2


Everolimus reduced bone marker levels and progressive disease in bone in BOLERO-2

Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M,Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI

J Nat Cancer Inst 2013; 105: 654-63

333

14,336IF:

Safety and Efficacy of Everolimus With Exemestane Versus Exemestane Alone in Elderly PatientsWith HER2-Negative, Hormone-Receptor-Positive Breast Cancer in BOLERO-2

Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csőszi T, Baselga J, Puttawibul P, PiccartM, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T,Sahmoud T, Gnant M

Clin Breast Cancer 2013, 13: 421-32

334

2,422IF:

Impact of Body Mass Index (BMI) on estradiol depletion by aromatase inhibitors in postmenopausalwomen with early breast cancer

Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M,Dubsky P

Br J Cancer 2013; 109: 1522-7

335

5,082IF:

Follow-up after breast cancer diagnosis

Thomssen C, Diel I, Gnant M, Goldmann-Posch U, Göschke C, Haidinger R, Janni W, Lin NU

Breast Care 2013; 8: 457-60

336

0,911IF:

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axillain breast cancer.

AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, GruberG, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F

Eur J Cancer 2013; 49: 2277-83

337

4,819IF:

Role of Bisphosphonates in postmenopausal women with breast cancer

Gnant M


338

6,024IF:

Standardization of morbidity assessment in breast cancer surgery using the Clavien DindoClassification

Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F

Int J Surg 2014; 12: 334-9

339

1,436IF:

Predicting distant recurrence in receptor-positive breast cancer patients with limitedclinicopathological risk: using the PAM50 score in 1,478 postmenopausal patients of the ABCSG-08trial treated with adjuvant endocrine therapy alone

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Singer C, Jakesz R, DubskyP, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens W, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T,on behalf of the ABCSG

Ann Oncol 2014; 25: 339-45

340

7,384IF:

Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying,enhanced postprandial release of GLP-1, and improved insulin sensitivity

Harmuth S, Wewalka M, Holst JJ, Nemecek R, Thalhammer S, Schmid R, Sahora K, Gnant M, Miholic J

J Gastrointest Surg 2014; 18: 52-9

341

2,361IF:

2


HER2-positive breast cancer: a new piece of the puzzle

Gnant M, Bartsch R, Steger GG

Lancet Oncol 2014; 15: 668-9

342

24,229IF:

Incidence and time course of everolimus-related adverse events in postmenopausal women withhormone-receptor-positive advanced breast cancer: insights from BOLERO-2

Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, ChouinardE, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hshimi M, Taran T, Sahmoud T, Burris HA

Ann Oncol 2014; 25: 808-15

343

7,384IF:

The impact of educational materials on compliance and persistence rates with adjuvant aromataseinhibitor treatment: first year results from the Compliance of ARomatase Inhibitors AssessmenT InDaily practice through Educational approach (CARIATIDE) Study

Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,Barni S, Deschamp V

Breast 2014; 23: 393-9

344

3,929IF:

The PAM50 risk-of-recurrence (ROR) score predicts risk for late distant recurrence after endocrinetherapy in postmenopausal women with endocrine-responsive early breast cancer: A study on 1,246patients from the ABCSG-8 trial

Filipits M, Nielsen T, Rudas M, Greil, R, Stöger H. Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C,Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C,Ferree S, Liu S, Cowens JW, Gnant M

Clin Cancer Res 2014; 20: 1298-305

345

7,837IF:

Present and Future Breast Cancer Management - Bench to Bedside and Back: A Positioning Paperof Academia, Regulatory Authorities and Pharmaceutical Industry

Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR,Llombart A, Massacesi C, vonMinckwitz G, Penult-Llorca F, Scaltriti M, Wein W, Yarden Y, Zwierzina H, Zielinski CC, forthe Biotherapy Development Association (BDA)

Ann Oncol 2014; 25: 773-80

346

7,384IF:

Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does notaffect mortality and morbidity after pancreatic resection

Sahora K, Schindl M, Kuehrer I, Werba G, Fitzal F, Goetzinger P, Gnant M

European Surgery 2013; in press DOI 10.1007/s10353-013-0213-0

347

0,148IF:

Taxanes plus Trastuzumab compared to oral Vinorelbine plus Trastuzumab in HER2-overexpressingmetastatic breast cancer patients

Bartsch R, Berghoff AS, Rudas M, Dubsky P, DeVries C, Sattlberger C, Mader MR, Sparber C, Fitzal F, Gnant M,Rottenfusser A, Zielinski CC, Preusser M, Steger GG

Cancer Chemotherapy and Pharmacology 2014 [in press]

348

2,795IF:

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathologicalcomplete response to taxan-based neoadjuvant chemotherapy

Foedermayr M, Sebesta M, Rudas M, Berghoff A, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger G,Welermann A, Zielinski C, Zach O, Bartsch R


349

2,571IF:

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breastcancer: final results of a randomized phase III study (ABCSG-24).

Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, StoegerH, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; onbehalf of the Austrian Breast and Colorectal Study Group (ABCSG

Ann Oncol 2014; 25:366-71

350

7,384IF:

2


Impact of the reconstruction method on delayed gastric emptying after pylorus-preservingpancreaticoduodenectomy: A prospective randomized study

Tamandl D, Sahora K, Prucker J, Schmid R, Holst JJ, Miholic J, Goetzinger P, Gnant M

World J Surg 2014; [published ahead of print Oct 12, 2013]

351

2,348IF:

The multigene signature MammaPrint® impacts on multidisciplinary team decisions in ER-positive,HER2-negative early breast cancer

Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl V, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R,Dubsky P

Brit J Cancer 2014; 111: 837-42

351

4,817IF:

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-yearbreast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomisedtrials.


Lancet 2014; 383: 2127-35

352

39,207IF:

Modern therapeutic concepts of early breast cancer

Gnant M

Breast Care (Basel) 2014; 92: 85-6

353

0,911IF:

Change of Body Mass Index (BMI) during adjuvant endocrine therapy and its impact on treatmentefficacy in premnopausal patients with breast cancer: an analysis of the ABCSG-12 trial

Pfeiler G, Königsberg R, Fesl C, Greil R, Stoeger H, Singer C, Knauer M, Steger G, Seifert M, Dubsky P, Fitzal F, Balic M,Bjelic-Radisic V, Mlineritsch B, Marth, C, Gnant M, on behalf of the ABCSG

Brit J Cancer 2014 [in press]

354

4,817IF:

Promoter methylation status of PCDH10, SPARC, and UCHL1 predict survival in stage II colorectalcancer patients treated with or without 5-fluorouracil-based chemotherapy

Heitzer E, Mach M, Filipits M, Resel M, Graf R, Weiszenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F,Boehm G, Hoefler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N

Modern Pathology 2014; 27: 906-15

356

7,837IF:

A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline andlocally advanced pancreatic cancer

Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, Teleky B, Ba'ssalamah A, Stift J, Schoppmann SF,Gnant M


357

1,872IF:

Preparing for prospective clinical trials - a national initiative of an excellence registry for consecutivepancreatic cancer resections

Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Laengle F, Oefner D, Mischinger HJ,Pratschke J, Gnant M, Fuegger R

World J Surg 2014; 38: 456-62

358

3,373IF:

The genomic expression test Endopredict® is a prognostic tool for identifying risk of local recurrencein postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomizedwithin the prospective ABCSG 8 trial

Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M

Brit J Cancer 2015 [in press]

359

4,817IF:

2


Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negativebreast cancer patients.

Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Gnant M, Steger GG,Weltermann A, Zielinski CC, Zach O, Bartsch R

J Hum Genetics 2015 [submitted]

360

IF:

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd,Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J.

Ann Oncol. 2014; 25: 2357-62

361

IF:

Co-overexpression of HER2/HER3 is a predictor of imparied survival in breast cancer patients

Berghoff A, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M,Fitzal F, Zielinski CC, Birner P

Breast 2014; 23: 637-43

362

2,581IF:

Cost-Effectiveness of prognostic gene expression signature-based stratification of early breastcancer patients

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD,Kronenwett R, Schwenkglenks M, Gnant M

Pharmacoeconomics 2015: 33: 179-90

363

IF:

The AURORA initiative for metastatic breast cancer.

Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C,Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A,Norton L, Piccart M.

Br J Cancer. 2014; 111: 1881-7

364

IF:

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis ofPatients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, TamoxifenAlone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M

J Clin Oncol 2014; Oct 20 online

365

18,370IF:

Patient-level meta-analysis of randomised trials of aromatase inhibitors versus tamoxifen in 31,920postmenopausal women with ER-positive early breast cancer

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*

Lancet 2015 [submitted]

366

IF:

Taxanes plus Trastuzumab compared to oral Vinorelbine plus Trastuzumab ind HER2-overexpressingmetastatic breast cancer

Bergen E, .............. Gnant M,...., Bartsch R

Breast Care 2015; [in press]

367

0,911IF:

Effects of adjuvant bisphosphonate treatment on early breast cancer disease outcomes: A meta-analysis ofindividual patient data from randomised trials

Coleman R, Powles T, Gnant M, bnm

Lancet 2015 [accepted]

368

20,000IF:

2


Ten-year analyses of the BIG 2-98 phase III trial with an exploratory analysis on the role of Ki67 inpredicting benefit of adjuvant docetaxel in patients with estrogen receptor positive breast cancer

Sonnenblick A, Azim HA Jr, de Azambuja E, Francis P, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, AmeyeL, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J

[submitted]

369

IF:

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plusovarian function suppression in premenopausal early breast cancer: of the Austrian Breast andColorectal Cancer Study Group Trial 12

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V,Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, on behalf of the ABCSG

Ann Oncol 2015; 26; 313-20

370

6,578IF:

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positivehormone receptor positive early stage breast cancer treated with endocrine therapy: A combinedanalysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and Intrinsic Subtype

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R,Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J

Ann Oncol 2015 [submitted]

371

6,578IF:

Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advancedrectal cancer--a phase II clinical trial.

Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F,Höfler G, Gnant M, Thaler J; ABCSG


372

1,872IF:

CDK4/6 inhibitors in luminal breast cancer

Gnant M, Steger GG, Bartsch R

Lancet Oncol 2015; 16: 2-3

373

24,725IF:

Activity of T-DM1 in HER2-positive breast cancer brain metastases

Bartsch R, Berghof AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, OehlerR, Zielinski CC, Gnant M, Steger GG, Preusser M

Neurooncology 2015 [submitted]

374

5,286IF:

Does patient education work in breast cancer? Final results from the global CARIATIDE study

Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,Barni S, Deschamp V

Future Oncol. 2015; 11: 205-17

375

IF:

Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from aEuropean Panel.

Hadji P*, Coleman RE*, Wilson C, Powles T, Clezardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, DiLeo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thuerlimann B, Untch M, Cortes J, Martin M, AlbertUS, Conte PF, Ejlertsen B, Bergh J, M Kaufmann, I Holen.

Ann Oncol 2015 [submitted]

376

IF:

2

Documents

Ohne Titel - chirurgiewien.at · Is orthotopic liver transplantation a feasable ... Prenephrectomy tissue typing using ... DNA ploidy and other results of DNA Flow cytometry as prognostic